Medicine reference
HMG (Human Menopausal Gonadotropin)
A source-linked medicine reference on HMG (Human Menopausal Gonadotropin), its documented context and safety boundaries. Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 March 2027.
Identity and scope
HMG commonly refers to menotropins. This reference uses the MENOPUR prescription label, which identifies FSH and LH activity in a fertility-treatment product.
Documented context
The label indicates development of multiple follicles and pregnancy in ovulatory women as part of an assisted-reproductive-technology cycle. That is not a general fertility or hormone claim.
Safety and a useful record
The label lists ovarian hyperstimulation syndrome, pulmonary and vascular complications, torsion and multiple gestation among important risks. This is specialist care, not a self-use context.
Record the named product, fertility-clinic plan, monitoring and urgent symptoms discussed by the treating team.
Published sources
- MENOPUR menotropins kit label
DailyMed / National Library of Medicine. Updated 31 May 2018; accessed 6 September 2026.
Supports: MENOPUR indication, contraindication and ovarian-hyperstimulation-risk context.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.